Page last updated: 2024-08-24

capecitabine and ridaforolimus

capecitabine has been researched along with ridaforolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cannistra, SA; Disis, ML; Verweij, J	1
Albanell, J; Berk, L; Capri, G; Cerny, T; Corradino, I; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Marsoni, S; Maur, M; Perotti, A; Rivera, VM; Rojo, F; Sessa, C; Viganò, L	1

Trials

1 trial(s) available for capecitabine and ridaforolimus

Article	Year
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome	2010

Article

Year

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome

2010

Other Studies

1 other study(ies) available for capecitabine and ridaforolimus

Article	Year
Phase I studies of drug combinations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome	2010

Article

Year

Phase I studies of drug combinations.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30

Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome

2010